482 related articles for article (PubMed ID: 18035676)
41. Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome.
Hsu CY; Kurman RJ; Vang R; Wang TL; Baak J; Shih IeM
Hum Pathol; 2005 Oct; 36(10):1049-54. PubMed ID: 16226103
[TBL] [Abstract][Full Text] [Related]
42. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
43. [Low grade malignant ovarian carcinomas. A retrospective study of 132 cases].
Randrianjafisamindrakotroka NS; Hedelin G; Philippe E; Schaffer P
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(7):761-7. PubMed ID: 1469230
[TBL] [Abstract][Full Text] [Related]
44. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
45. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
46. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
47. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
48. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
49. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
50. [Paradigm Shift in Ovarian Tumor Pathology from the View of Genomic Abnormalities].
Mikami Y
Gan To Kagaku Ryoho; 2016 Mar; 43(3):286-9. PubMed ID: 27067843
[TBL] [Abstract][Full Text] [Related]
51. [Phenotype--genotype--correlation in ovarian neoplasia].
Diebold J
Verh Dtsch Ges Pathol; 2001; 85():153-60. PubMed ID: 11894392
[TBL] [Abstract][Full Text] [Related]
52. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium.
Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959
[TBL] [Abstract][Full Text] [Related]
53. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.
Kurman RJ; Shih IeM
Hum Pathol; 2011 Jul; 42(7):918-31. PubMed ID: 21683865
[TBL] [Abstract][Full Text] [Related]
54. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
55. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas.
Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L
Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906
[TBL] [Abstract][Full Text] [Related]
56. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas.
Pere H; Tapper J; Wahlström T; Knuutila S; Butzow R
Cancer Res; 1998 Mar; 58(5):892-5. PubMed ID: 9500445
[TBL] [Abstract][Full Text] [Related]
57. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours.
Abeln EC; Smit VT; Wessels JW; de Leeuw WJ; Cornelisse CJ; Fleuren GJ
J Pathol; 1997 Dec; 183(4):424-31. PubMed ID: 9496259
[TBL] [Abstract][Full Text] [Related]
58. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
59. [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].
Staebler A; Diebold J
Pathologe; 2007 May; 28(3):180-6. PubMed ID: 17431628
[TBL] [Abstract][Full Text] [Related]
60. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis.
Pere H; Tapper J; Seppälä M; Knuutila S; Butzow R
Cancer Res; 1998 Oct; 58(19):4274-6. PubMed ID: 9766651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
